Evidence map›Paper›PMID 38943670›Full record

ArticleJournal of the Pediatric Infectious Diseases Society2024

Hepatitis B Elimination Globally: The Answer May Not Be the Same for Everyone.

Peyton Thompson

Abstract read
In one paragraph

Article in Journal of the Pediatric Infectious Diseases Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Peyton ThompsonDivision of Infectious Diseases, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0002-9679-9763

Funding

Characterizing Hepatitis B Transmission in Congolese ChildrenK08AI148607 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI THOMPSON, PEYTON J · 2020 to 2024
$1.0M
NIAID NIH HHS K08 AI148607
6 · The paper itself

Abstract

While progress has been made toward global elimination of hepatitis B virus, many countries lag behind. A one-size-fits-all approach is not practical to address HBV. Rather, the approach should be tailored to local prevalence, risk factors, and available resources.

Indexed as

Disease EradicationGlobal HealthHepatitis BHepatitis B VaccinesHepatitis B virusHumansPrevalenceRisk FactorsHepatitis B Vaccineschronic HBV infectionglobal hepatitis eliminationhepatitis B virus (HBV)HepB vaccinationpublic health prevention

Identifiers

PMID38943670
PMCPMC12104502

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.